Vir Biotechnology Prices $141.1M Public Offering at $8.50/Share

summarizeSummary

Vir Biotechnology entered into an underwriting agreement to sell 17.65 million shares of common stock at $8.50 per share, with an option for underwriters to purchase an additional 2.65 million shares, expecting net proceeds of up to $162.3 million.

check_boxKey Events

• Public Offering Priced

  Vir Biotechnology entered an underwriting agreement to sell 17,647,059 shares of common stock at a public offering price of $8.50 per share.

• Significant Capital Raise

  The offering is expected to generate net proceeds of approximately $141.1 million, potentially reaching $162.3 million if the underwriters fully exercise their option to purchase additional shares.

• Underwriter Option Granted

  Underwriters have a 30-day option to purchase up to an additional 2,647,058 shares of common stock at the public offering price.

• Follows Recent Collaboration

  This capital raise follows the company's recent global collaboration with Astellas, which included $315 million in upfront and near-term funding, suggesting a strategic move to further strengthen its financial runway.

auto_awesomeAnalysis

This 8-K filing announces the final pricing and terms of a substantial public offering, following the S-3 registration statement filed in November 2023. The company will raise approximately $141.1 million, potentially increasing to $162.3 million if the underwriters' option is fully exercised. While dilutive for existing shareholders, this capital raise significantly bolsters the company's financial position, enabling it to fund ongoing operations and advance its pipeline. This comes shortly after the company announced a major global collaboration with Astellas, including $315 million in upfront and near-term funding, indicating an aggressive strategy to capitalize on recent successes and accelerate development.